Billionaire hedge fund manager Ken Griffin increased Citadel’s position in AbbVie (NYSE: ABBV) by more than 500% during the second quarter of 2026.
Griffin’s moves are closely watched by investors who use legally required 13F filings to track where major fund managers are placing their capital.
The AbbVie buy is widely viewed as a defensive play, given that healthcare spending remains resilient even during periods of economic stress and market volatility.
JPMorgan Chase (NYSE: JPM) CEO Jamie Dimon has warned that multiple geopolitical conflicts, high inflation, and elevated leverage are like “tectonic plates” that could collide and cause material market disruptions.
Against that backdrop, a stable healthcare stock with a long dividend track record holds clear appeal for investors seeking shelter from potential downturns.
AbbVie carries a dividend yield of 2.6%, which sits well above the broader market average and adds an income layer to its defensive characteristics.
The company is a member of the Dividend Kings club, having delivered more than 50 consecutive annual dividend increases, a streak that traces back to its spinoff from Abbott (NYSE: ABT).
AbbVie has increased its dividend every year since that spinoff, demonstrating a consistent commitment to returning value to shareholders through income distributions.
On the business side, AbbVie appears to have successfully navigated a significant patent cliff, replacing lost Humira revenue with newer drugs Skyrizi and Rinvoq.
The company’s aesthetics segment has also remained solid despite Botox losing patent protection, with brand value continuing to play a meaningful role in that competitive niche.
AbbVie’s acquisition of Apogee further strengthens the company’s pipeline, bringing drug candidates in the dermatologic, respiratory, inflammatory, and immunological spaces.
The stock is not cheap by conventional measures, with both its price-to-sales and price-to-earnings ratios currently sitting above their five-year averages.
Despite the premium valuation, 25 of the 31 Wall Street analysts currently tracking ABBV rate it a buy, reflecting broad confidence in the company’s forward trajectory.
The consensus average price target among those analysts stands at $277, which remains above where the stock is currently trading in the market.
For investors concerned about market instability, AbbVie’s combination of a strong drug portfolio, reliable dividend growth, and Wall Street backing makes it a stock worth examining closely.
